Plain-English translation of NCT06861543 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-phase trial (Phase 1) testing a medication called in people with advanced pancreatic cancer or non-small cell lung cancer whose standard treatments have failed or caused unbearable side effects. Researchers are starting with low doses and gradually increasing them to find the safest, most effective dose. The trial will enroll about 18 patients total and monitor them carefully for safety and signs of how well the treatment works.
People with advanced pancreatic cancer and non-small cell lung cancer who have exhausted standard treatment options need new options. This trial is exploring whether this medication could offer hope when other approaches have stopped working or become too difficult to tolerate.
You likely qualify if…
You likely don't qualify if…
You would receive an intramuscular injection of the medication once per week for 9 weeks total. Your doctor will start you on the lowest dose and may adjust based on how you respond and tolerate the treatment. At week 6, you'll have scans to see how your cancer is responding, and your doctor will decide whether to continue, adjust, or stop treatment based on those results. You'll have regular visits and blood tests to monitor your health and watch for side effects throughout the trial.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China